Battlestar is our patented first-in-class antimicrobial delivery system that safely and stably releases oxidative biocides—peracetic acid and hydrogen peroxide—directly at the site of infection.
AGA Nanotech is safeguarding tomorrow by innovating against antimicrobial resistance today
Why AMR Matters & The Clinical Need
Antimicrobial resistance (AMR) is a global health crisis. The overuse and misuse of antibiotics have led to the emergence of drug-resistant bacteria, making infections harder to treat and increasing the risk of disease spread, severe illness, and death. AMR threatens the very foundations of modern medicine, jeopardizing the safety of surgeries, cancer treatments, and organ transplants. The clinical need to address AMR is urgent and critical. Explore how we are tackling this challenge and the importance of innovative solutions in safeguarding human health.
Learn MoreMeet the AGA Nanotech Team
Our team is composed of passionate scientists, researchers, and industry experts dedicated to combating AMR. With a wealth of experience and a shared vision for a healthier future, we are committed to driving innovation and delivering impactful solutions. Get to know the people behind AGA Nanotech.
Partners in Innovation
Collaboration is key to our success. We work with leading research institutions, healthcare providers, and industry partners to advance our technology to bring our solutions to those who need them most. Learn more about our partners and how we are working together to fight AMR.
Latest News
AGA Nanotech Wins 2025 EWMA Innovation Award for Battlestar™ Antimicrobial Technology
Recognition from Europe’s leading wound care network highlights Battlestar™ as a breakthrough antimicrobial platform that combats infections without antibiotics
AGA Nanotech to Attend AMR Conference in Basel as Part of Innovate UK GBIP Switzerland
At the 9th AMR Conference, AGA Nanotech will demonstrate Battlestar™, its non-antibiotic antimicrobial solution offering sustained efficacy across critical clinical applications.
AGA Nanotech Tackles Biofilms in Bone Infections Through MSK Innovation Accelerator
Participating in a six-month programme, AGA Nanotech will advance Battlestar™ for osteomyelitis, supported by clinical and industry expertise to AMR in musculoskeletal infections.